

Assessing the credibility of computational modeling and simulation for medical devices: Final FDA Guidance

Pras Pathmanathan, PhD

Division of Biomedical Physics

Office of Science and Engineering Laboratories (OSEL)

Center for Devices and Radiological Health (CDRH)

FDA


Acknowledgements



Kenneth Aycock
OSEL/DAM
Kenneth.Aycock@fda.hhs.gov



Brent Craven
OSEL/DAM
Brent.Craven@fda.hhs.gov



Pras Pathmanathan
OSEL/DBP
Pras.Pathmanathan@fda.hhs.gov

What is computational modeling and simulation (CM&S)?

Data-driven models

- Statistical methods, e.g., regression
- Machine learning and AI



Hybrid methods

- First-principles model with data-driven sub-model(s)
- Train ML model to first-principles model results
- Physics-informed neural networks

First-principles models

- Physics-based models
- Mechanistic models

Mathematical models



What is computational modeling and simulation (CM&S)?

Data-driven models

- Statistical methods, e.g., regression
- Machine learning and AI




Hybrid methods

- First-principles model with data-driven sub-model(s)
- Train ML model to first-principles model results
- Physics-informed neural networks

First-principles models

- Physics-based models
- Mechanistic models


Mathematical models



CM&S in regulatory submissions


In Silico Device Testing

Simulate device to generate safety/effectiveness evidence



CM&S in device software


Algorithm in device software takes in patient data and simulates the patient




CardioInsight

In Silico Clinical Trial

Device performance is evaluated using a 'virtual cohort' of simulated patients.




CM&S-based MDDT



IMAnalytics

Timeline



CDRH M&S Reporting Guidance




OSEL Credibility of Models Regulatory Science Program




~2010
Growing awareness in devices community (incl. CDRH) of need for standardized credibility assessment

2013
ASME V&V40 subcommittee formed

2016
ASME V&V40 Standard



2020
Draft Guidance




2021
Final Guidance

Key Definitions

Paraphrased from Credibility Guidance, originally from ASME V&V40 2018:

- **Credibility** – “the trust, based on all available evidence, on the predictive capability of a computational model”
- **Context of use (COU)** – “the role and scope of the computational model in answering the question of interest”



Scope of the guidance

In scope

- First principles-based models
- For hybrid models:
 - First-principles model components




Out of scope models

- Standalone statistical or data-driven models
- Models with no simulation, e.g., anatomical models

Also out of scope

- How to perform modeling studies
- Technical details for how to perform credibility assessment
- Specific level of credibility needed for regulatory submissions

ASME V&V40 2018




Activities		Credibility Factors
Verification	Code	Software Quality Assurance
		Numerical Code Verification
	Calculation	Discretization Error
		Numerical Solver Error
Validation	Computational Model	Use Error
		Model Form
	Comparator	Model Input
		Test Samples
		Test Conditions
Assessment	Equivalency of Input Parameters	
	Output Comparison	
Applicability		Relevance of the Quantities of Interest
		Relevance of the Validation Activities to the COU

Guidance – key points and approach

- Consistent with ASME V&V40-2018
 - **Risk-informed** credibility assessment
 - Can follow Guidance by following V&V40
 - Emphasis on **question of interest, context of use and model risk**

- Provides a general framework for model credibility assessment
 - Intended to be applicable to **all** CM&S models, applications and types of regulatory submission
 - **Not prescriptive**

- Framework extends approach of ASME V&V40 2018
 - ASME V&V40 implicitly assumes validation against prospective well-controlled bench tests




Guidance – key points and approach

- Consistent with ASME V&V40-2018
 - **Risk-informed** credibility assessment
 - Can follow Guidance by following V&V40
 - Emphasis on **question of interest, context of use and model risk**

- Provides a general framework for model credibility assessment
 - Intended to be applicable to **all** CM&S models, applications and types of regulatory submission
 - **Not prescriptive**

- Framework extends approach of ASME V&V40 2018
 - ASME V&V40 implicitly assumes validation against prospective well-controlled bench tests




Guidance – key points and approach

- Consistent with ASME V&V40-2018
 - **Risk-informed** credibility assessment
 - Can follow Guidance by following V&V40
 - Emphasis on **question of interest, context of use and model risk**

- Provides a general framework for model credibility assessment
 - Intended to be applicable to **all** CM&S models, applications and types of regulatory submission
 - **Not prescriptive**


- Framework extends approach of ASME V&V40 2018
 - ASME V&V40 implicitly assumes validation against prospective well-controlled bench tests




Framework



Guidance Figure 1:



Framework




Step 1: state the Question of Interest

“the specific question, decision, or concern that is being addressed”

- Should be about the real world
- Not about the model
- Should not be overly broad (i.e., not “Is the device safe?”)

Device testing example

Is the device resistant to fatigue fracture under anticipated worst-case radial loading conditions?



Step 2: state the **Context of Use**

“the role and scope of the computational model in answering the question of interest”

- what is modeled and how model outputs used to answer the question of interest
- type of modeling, key inputs and outputs
- whether other information (e.g., bench/animal/clinical) will be used to answer the question of interest


Device testing example

Combine computational modeling predictions and empirical fatigue testing observations to estimate device fatigue safety factors under anticipated worst-case radial loading conditions [...]


Step 3: assess Model Risk

“the possibility that the computational model and the simulation results may lead to an incorrect decision that would lead to an adverse outcome”

- Broken down into **model influence** and **decision consequence**
- Decision consequence
 - significance of an adverse event following an incorrect decision
 - essentially “Risk” as defined in ISO 14971
 - Therefore, recommend sponsors consider probability of occurrence and severity of harms



Framework





Step 4: Identify **Credibility Evidence** to be collected

“any evidence that could support the credibility of a computational model”

- Evidence categorization provided (right)
- **Details and device-specific examples** for each category provided in Section VI.B
- Specific **recommendations** for each category in Appendix 1

1	Code verification results
2	Model calibration evidence
3	Bench test validation results
4	<i>In vivo</i> validation results
5	Population-based validation results
6	Emergent model behavior
7	Model plausibility evidence
8	Calc. verification/UQ using COU conditions



Step 5: Credibility Factors


For each set of evidence:

- Define credibility factors (some recommended factors provided)
- For each factor
 - Define a gradation of activities
 - Choose a target level based on the risk assessment

Example

3

Bench test validation results



Appendix 1 recommends using relevant ASME V&V40 factors

Activities		Credibility Factors
Verification	Code	Software Quality Assurance
		Numerical Code Verification
	Calculation	Discretization Error
		Numerical Solver Error
Validation	Computational Model	Model Form
		Model Input
	Comparator	Test Samples
		Test Conditions
	Assessment	Equivalency of Input Parameters
Applicability		Output Comparison
		Relevance of the Quantities of Interest
		Relevance of the Validation Activities to the COU

Gradation from ASME V&V40 2018

- (a) A single sample was used.
- (b) Multiple samples were used, but not enough to be statistically relevant.
- (c) A statistically relevant number of samples were used.

See ASME V&V40 2018

Step 5: Credibility Factors


For each set of evidence:

- Define credibility factors (some recommended factors provided)
- For each factor
 - Define a gradation of activities
 - Choose a target level based on the risk assessment

Example

3

Bench test validation results



Appendix 1 recommends using relevant ASME V&V40 factors


Activities		Credibility Factors
Verification	Code	Software Quality Assurance
		Numerical Code Verification
	Calculation	Discretization Error
		Numerical Solver Error
Validation	Computational Model	Use Error
		Model Form
	Comparator	Model Input
		Test Samples
	Assessment	Test Conditions
		Equivalency of Input Parameters
Applicability		Output Comparison
		Relevance of the Quantities of Interest
		Relevance of the Validation Activities to the COU

Gradation from ASME V&V40 2018

- (a) A single sample was used.
- (b) Multiple samples were used, but not enough to be statistically relevant.
- (c) A statistically relevant number of samples were used.

See ASME V&V40 2018

Framework



Step 8: Rationale for Adequacy


Does the credibility evidence support using the model for the COU given risk assessment?

- Subjective decision based on all available evidence and engineering/clinical judgement
- Considerations
 - All relevant model features tested?
 - If credibility goals not met, consider providing a rationale for why results still adequate
 - How do predictions with uncertainties compare to decision/safety thresholds?
 - Discuss limitations of model

Overview of related efforts

Regulatory Science Tools

Standard




Guidance

Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions

Guidance for Industry and Food and Drug Administration Staff

Example workflow for **patient-specific models**



Example workflow for **in silico clinical trials**



In silico clinical trials “playbook”



CM&S mock submission



Credibility assessment **toolbox**



Detailed credibility assessment **examples**



Discussed today

Ongoing efforts

Possible future efforts



See OSEL website for current regulatory science tools

Regulatory Science Tools



- “A peer-reviewed resource for medical device companies to use where standards and qualified Medical Device Development Tools (MDDTs) do not yet exist”
- Can be used by industry to generate data in support of device safety/effectiveness
- OSEL primary type of deliverable



See OSEL website for current regulatory science tools

Catalog of Regulatory Science Tools to Help Assess New Medical Devices



Science and Research | Medical Devices

Catalog of Regulatory Science Tools to Help Assess New Medical Devices

Medical Device Material Safety Summaries

CDRH Regulatory Science Priorities

Database for Reference Grade Microbial Sequences (FDA-ARGOS)

Medical Device Regulatory Science Research Programs Conducted by OSEL



Content current as of: 11/06/2023

Regulated Product(s) Medical Devices

Update October 02, 2023: The FDA updated the catalog to add 9 new tools and update 3 tools.

New:

- [An In Vitro Blood Flow Loop System for Thrombogenicity Evaluation of Medical Devices and Biomaterials](#)
- [Chemical RISK calculators \(CHRIS\) – Bulk Chemicals \(v2\)](#)
- [Chemical RISK calculators \(CHRIS\) – Color Additives \(v2\)](#)
- [Chemical RISK calculators \(CHRIS\) – Extraction Efficiency](#)
- [LCD-CT: Low-contrast Detectability \(LCD\) Test for Assessing Advanced Nonlinear CT Image Reconstruction and Denoising Methods](#)
- [Mechanical and Leakage Integrity Testing Protocols for Evaluating the Performance of Tissue Containment Systems Used During Power Morcellation Procedures](#)

Summary and Key Points

- Mathematical modeling has a plethora of possible regulatory applications for medical devices
 - *In silico* device testing
 - Within device software – including digital twins
 - *In silico* clinical trials
- For CM&S, there are many possible ways to evaluate the models
 - Challenging to develop a coherent and comprehensive regulatory strategy
- FDA is addressing this through Guidance providing a general framework relevant to all modeling fields and submission types
 - Not prescriptive
 - Further assistance for industry provided through Regulatory Science Tools
 - There is a need for future field/device-specific prescriptive standards

Thank you for your attention

Acknowledgments

- Kenny Aycock (FDA)
- Andreu Badal (FDA)
- Jeff Bodner (Medtronic)
- Ramin Bighamian (FDA)
- Brent Craven (FDA)
- Suran Galappaththige (FDA)
- Richard Gray (FDA)
- Caroline Mendonca Costa (King's College London)
- Tina Morrison (FDA)
- Steve Niederer (Imperial)